HORIZONS HOT BIOPSY FORCEPS
K021706 · Horizons Intl. Corp. · KGE · Jun 21, 2002 · Gastroenterology, Urology
Device Facts
| Record ID | K021706 |
| Device Name | HORIZONS HOT BIOPSY FORCEPS |
| Applicant | Horizons Intl. Corp. |
| Product Code | KGE · Gastroenterology, Urology |
| Decision Date | Jun 21, 2002 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.4300 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
Horizons Hot Biopsy Forceps is intended to be used in the flexible endescope for transendoscopic, dissecting, and grasping tissue for biopsy.
Device Story
Horizons Hot Biopsy Forceps; electrosurgical accessory used with flexible endoscopes. Device enables physician to grasp and dissect tissue samples during endoscopic procedures. Operates by delivering electrical current to tissue via forceps jaws; facilitates biopsy collection. Used in clinical settings by trained physicians. Provides mechanical grasping and electrosurgical cutting/coagulation capabilities; aids in diagnostic tissue sampling.
Clinical Evidence
No clinical data provided; substantial equivalence based on design and intended use.
Technological Characteristics
Electrosurgical accessory for flexible endoscopes; designed for tissue grasping and dissection. Class II device (21 CFR 876.4300).
Indications for Use
Indicated for use with flexible endoscopes for transendoscopic tissue dissection and grasping for biopsy purposes. Intended for prescription use only.
Regulatory Classification
Identification
An endoscopic electrosurgical unit and accessories is a device used to perform electrosurgical procedures through an endoscope. This generic type of device includes the electrosurgical generator, patient plate, electric biopsy forceps, electrode, flexible snare, electrosurgical alarm system, electrosurgical power supply unit, electrical clamp, self-opening rigid snare, flexible suction coagulator electrode, patient return wristlet, contact jelly, adaptor to the cord for transurethral surgical instruments, the electric cord for transurethral surgical instruments, and the transurethral desiccator.
Related Devices
- K022243 — HORIZONS REUSABLE HOT BIOPSY FORCEPS · Horizons Intl. Corp. · Oct 25, 2002
- K180018 — Disposable Hot Biopsy Forceps · Micro-Tech (Nanjing) Co., Ltd. · Jul 5, 2018
- K160625 — Disposable Hot Biopsy Forceps · Micro-Tech (Nanjing) Co., Ltd. · Jun 14, 2016
- K090796 — MULTI-BITE HOT BIOPSY FORCEPS · Endo-Therapeutics, Inc. · Nov 25, 2009
- K101657 — RADIAL 4 HOT BIOPSY FORCEPS BOX 5; RADIAL JAW 4 HOT BIOPSY FORCEPS BOX 20; RADIAL JAW 4 HOT BIOPSY FORCEPS BOX 40 · Boston Scientific Corp · Oct 5, 2010
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an image of three stylized human profiles facing to the right, with three bars above them.
## Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
## JUN 2 1 2002
Mr. Rafic Saleh President Horizons International Corp. 287 Monterrey Street PONCE PR 00717-1376
Re: K021706
Trade/Device Name: Horizons Hot Biopsy Forceps Regulation Number: 21 CFR 876.4300 Regulation Name: Endoscopic electrosurgical unit and accessories Regulatory Class: II
Product Code: 78 KGE Dated: May 14, 2002 Received: May 23, 2002
Dear Mr. Saleh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 8xx.1xxx | (301) 594-4591 |
|----------------------------------|----------------|
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |
Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Nancy C. Brogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Ko 21706 Page 1 of 1
乐
6.1 Indication for Use
## 510K INDICATION FOR USE STATEMENT
510(k) Number (if known): K021706
Horizons Hot Biopsy Forceps Device Name:
Horizons International Corp. Applicant Name:
Indications for Use:
Horizons Hot Biopsy Forceps is intended to be used in the flexible endescope for transendoscopic, dissecting, and grasping tissue for biopsy.
Horizons International Corp.
Signature: Date: 6/18/02
Rafic Saleh - President
Prescription Use (Per 21 CFR 801.109)
David W. Legum
(Division Sign-Off) Division of Reproductive, A and Radiological Device 510(k) Number
{3}------------------------------------------------
K021706 Page 1 of 1
## 510K STATEMENT OF SAFETY AND EFFECTIVENESS:
I certify, in my capacity as President of Horizons International Corporation, I will make available all information included in this premarket notification on safety and effectiveness within 30 days of request by any person if the device is determined to be substantially equivalent. The information made available will be a duplicate of the premarket notification submission, including any adverse safety and effectiveness information, but excluding all patient identifiers, and trade secret and confidential commercial information, as defined in 21CFR20.61.
Rafic Saleh - President
5/22/02
Date